Studieoverzicht
BOOG nr.: |
Status: ( Active, not recruiting )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2022-01 DIRECT-2 | Active, not recruiting | Neoadjuvant | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-04 TROPION-Breast01 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-03 EMBER-3 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-02 ZEST | Active, not recruiting | Adjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2020-02 AMEERA-5 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2020-01 DESTINY-Breast 06 | Active, not recruiting | Advanced/metastatic | Any HER2, HR+ | Both pre- and postmenopausal | ||||||||||||||
2019-01 TIBET | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2017-03 SONIA | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Not applicable | ||||||||||||||
2013-01 TRIPLE-B | Active, not recruiting | Advanced/metastatic | TNBC | Both pre- and postmenopausal |